CeQur raises $120M to support insulin delivery tech
January 7, 2025
Insulin delivery technology developer CeQur today announced a significant funding round to support its commercialization efforts.
Insulin delivery technology developer CeQur today announced a significant funding round to support its commercialization efforts.
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant.
MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.
The clearance paves the way for the launch of Medtronic’s Smart MDI system, which combines its InPen and Simplera continuous glucose monitor for people who take multiple daily insulin injections.
Dexcom’s third-quarter earnings report included news of a significant submission to the FDA for the company’s latest-generation technology.
Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S.
Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.
Abbott (NYSE: ABT)+
today announced a major product launch, broadening the population that can utilize its continuous glucose monitoring (CGM) technology.
Embecta (Nasdaq:EMBC) today entered the insulin patch pump market with a major regulatory milestone.
The FDA clearance marks the first automated insulin delivery system for people with Type 2 diabetes.